Form 4: Silence Therapeutics Director and 10% Owner Richard Griffiths Increases Stake with Significant Share Purchases

Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc, has significantly increased his beneficial ownership through the acquisition of American Depositary Shares on May 22 and May 23, 2025.

Summary

• Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc (SLN), acquired additional American Depositary Shares (ADSs).
• On May 22, 2025, Mr. Griffiths purchased 19,174 ADSs at a price of $5.04 per ADS.
• These 19,174 ADSs represent an underlying beneficial ownership of 57,522 ordinary shares (each ADS is convertible into three ordinary shares).
• On May 23, 2025, an additional 17,187 ADSs were acquired at a price of $4.92 per ADS.
• These 17,187 ADSs represent an underlying beneficial ownership of 51,561 ordinary shares.
• Following these transactions, Mr. Griffiths' direct beneficial ownership stands at 11,236,237 ordinary shares (derived from ADSs).

Sentiment

Score: 8

Explanation: The sentiment is positive due to significant insider buying by a director and 10% owner, indicating strong confidence in the company's future performance and valuation.

Positives

• A Director and 10% owner, Richard Ian Griffiths, has increased his stake in Silence Therapeutics plc, indicating confidence in the company's future prospects.
• The acquisition of additional shares by a significant insider suggests alignment of interests between management/large shareholders and other investors.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider purchases, especially by a director and significant owner, can be interpreted as a positive signal within the biotechnology or pharmaceutical industry, suggesting confidence in the company's pipeline, clinical trials, or commercialization prospects, particularly in a sector often characterized by high R&D costs and regulatory hurdles.

Comparison to Industry Standards

• This Form 4 filing reports specific insider transactions and does not provide company performance metrics that can be directly compared to global industry benchmarks or specific comparable companies/projects. However, insider buying is generally viewed favorably across all industries as it signals management's belief in the company's undervaluation or strong future performance.

Related Party Transactions

• The reported transactions are related party transactions as they involve a Director and 10% owner of Silence Therapeutics plc acquiring shares of the company.

Stakeholder Impact

• Shareholders: Likely positive, as insider buying often signals confidence and can lead to increased investor interest and potentially a higher share price.
• Employees: No direct impact mentioned, but a positive market sentiment could indirectly boost morale.
• Customers/Suppliers/Creditors: No direct impact from this specific filing.

Key Dates

Recommendation

Keywords

Silence Therapeutics, SLN, Form 4, Insider Trading, Share Purchase, Director, 10% Owner, Richard Ian Griffiths, American Depositary Shares, Equity Acquisition